Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
REGULATORY
Probable Cases of Mysterious Pediatric Hepatitis Now Increased to 7 in Japan
A total of seven “probable” cases of pediatric acute hepatitis of unknown origin have now been detected in Japan, with an addition of four new cases reported, the Japanese health ministry said on May 6. According to the WHO’s tentative…
To read the full story
Related Article
- Japan Detects 14 More Probable Cases of Pediatric Hepatitis
September 20, 2022
- 8 New Probable Cases of Pediatric Hepatitis Reported in Japan
July 26, 2022
- Japan Detects 4 More Probable Cases of Pediatric Hepatitis
July 11, 2022
- 5 New Probable Cases of Pediatric Hepatitis Reported in Japan
July 4, 2022
- Japan Finds 4 More Probable Cases of Acute Hepatitis in Children
June 27, 2022
- Japan Detects 11 More Probable Cases of Mysterious Hepatitis in Children
June 20, 2022
- Japan Confirms 11 More Probable Cases of Acute Hepatitis in Children
June 13, 2022
- Japan Reports 5 More Probable Cases of Acute Hepatitis in Children
June 6, 2022
- 7 New Probable Cases of Pediatric Hepatitis Reported in Japan
May 31, 2022
- 12 New Probable Cases of Mysterious Pediatric Hepatitis Detected in Japan
May 23, 2022
- 5 New Probable Cases of Acute Pediatric Hepatitis Found in Japan
May 16, 2022
REGULATORY
- JPMA Urges Foreign Price Rule Overhaul to Address US MFN Policy: LDP Hearing
November 5, 2026
- MOF Presses for Full FY2027 Drug Price Revision Without Price Gap Thresholds
November 4, 2026
- Japan Panel to Review Kyowa Kirin’s Libmeldy for Approval on Nov. 9
November 4, 2026
- PMDA Sets Out AI Principles for Regulatory Activities, Stresses Human Oversight
November 4, 2026
- Public-Private Pharma Talks Expand to Domestic R&D, Manufacturing Investment
November 2, 2026
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…